By Dr Brittney Harrington

Journal articles

Kudo K; Greer YE; Crooks DR; Yang Y; Brender JR; Yoshida T; Harrington BS; Kamdar R; Korrapati S; Shibuya Y; Henegar L; Kopp J; Fujii T; Lipkowitz S; Annunziata CM, 2025, 'Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer', Cell Death and Disease, 16, http://dx.doi.org/10.1038/s41419-025-07672-3

Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM, 2024, 'Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer', Cancer Gene Therapy, 31, pp. 721 - 735, http://dx.doi.org/10.1038/s41417-024-00748-w

Harrington BS; Kamdar R; Ning F; Korrapati S; Caminear MW; Hernandez LF; Butcher D; Edmondson EF; Traficante N; Hendley J; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Nag ML; Mazan-Mamczarz K; House CD; Hooper JD; Annunziata CM, 2023, 'UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer', Journal of Experimental and Clinical Cancer Research, 42, pp. 270, http://dx.doi.org/10.1186/s13046-023-02820-z

Kamdar RD; Harrington BS; Attar E; Korrapati S; Shetty J; Zhao Y; Tran B; Wong N; House CD; Annunziata CM, 2023, 'NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms24097826

Kudo K; Harrington BS; Ning F; Kamdar R; Shibuya Y; Korrapati S; Fergusson M; Kucera C; Massimo F; Annunziata CM, 2023, 'New therapeutic strategies suppressing NAD plus and ATP production in cancer metabolism specific to 3D cultured ovarian cancer cells', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.AM2023-488

Kamdar RD; Harrington BS; Korrapati S; Attar E; Wong N; House CD; Annunziata CM, 2023, 'NF-κB classical and alternative signaling differentially regulate miRNA expression in ovarian cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.AM2023-3781

Anand P; Wilson J; Carter B; Bronstein A; Schwartz A; Harrington B; Adams T; Saine ME; Norris A; Metzger D; Short WR; Torgersen J, 2022, 'Clinic screening for adverse childhood experiences in people living with HIV to Improve Care Delivery', AIDS Care, 34, pp. 1094 - 1102, http://dx.doi.org/10.1080/09540121.2021.1956416

Harrington BS; Kamdar R; Wong N; House CD; Annunziata CM, 2022, 'Abstract 3188: Modulating UGDH expression in ovarian cancer tumor-initiating cells alters the tumor microenvironment', Cancer Research, 82, pp. 3188 - 3188, http://dx.doi.org/10.1158/1538-7445.am2022-3188

Kamdar RD; Harrington BS; Korrapati S; Wong N; House CD; Annunziata CM, 2022, 'Abstract 5820: NF-κB signaling regulates miRNA expression in ovarian cancer', Cancer Research, 82, pp. 5820 - 5820, http://dx.doi.org/10.1158/1538-7445.am2022-5820

Caminear MW; Harrington BS; Kamdar RD; Kruhlak MJ; Annunziata CM, 2022, 'Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells', Frontiers in Oncology, 12, http://dx.doi.org/10.3389/fonc.2022.762820

Caminear M; Harrington B; Annunziata C, 2021, 'Abstract 1011: Disulfiram superior to ALDH1A1 inhibitor analogs in targeting ovarian cancer stem cells', Cancer Research, 81, pp. 1011 - 1011, http://dx.doi.org/10.1158/1538-7445.am2021-1011

Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD, 2021, 'Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1', Nature Chemical Biology, 17, pp. 776 - 783, http://dx.doi.org/10.1038/s41589-021-00783-w

Harrington BS; Ozaki MK; Caminear MW; Hernandez LF; Jordan E; Kalinowski NJ; Goldlust IS; Guha R; Ferrer M; Thomas C; Shetty J; Tran B; Wong N; House CD; Annunziata CM, 2020, 'Drugs targeting tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model', Cancers, 12, pp. 1 - 21, http://dx.doi.org/10.3390/cancers12061645

Khan T; He Y; Kryza T; Harrington BS; Gunter JH; Sullivan MA; Cuda T; Rogers R; Davies CM; Broomfield A; Gough M; Wu AC; McGann T; Weroha SJ; Haluska P; Forbes JM; Armes JE; Barry SC; Coward JI; Jagasia N; Chetty N; Snell CE; Lourie R; Perrin LC; Hooper JD, 2020, 'Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma', Cancers, 12, http://dx.doi.org/10.3390/cancers12040869

He Y; Davies CM; Harrington BS; Hellmers L; Sheng Y; Broomfield A; McGann T; Bastick K; Zhong L; Wu A; Maresh G; McChesney S; Yau Wong K; Adams MN; Sullivan RC; Palmer JS; Burke LJ; Ewing AD; Zhang X; Margolin D; Li L; Lourie R; Matsika A; Srinivasan B; McGuckin MA; Lumley JW; Hooper JD, 2020, 'CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin', Oncogene, 39, pp. 219 - 233, http://dx.doi.org/10.1038/s41388-019-0983-3

Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BWC; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD, 2020, 'Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer', Theranostics, 10, pp. 2095 - 2114, http://dx.doi.org/10.7150/thno.30736

Harrington BS; Annunziata CM, 2020, 'Drugs targeting ovarian cancer tumor-initiating cells enhance oxidative stress and prevent disease recurrence', CANCER RESEARCH, 80, http://dx.doi.org/10.1158/1538-7445.AM2020-3582

Harrington BS; Annunziata CM, 2019, 'Nf-κb signaling in ovarian cancer', Cancers, 11, http://dx.doi.org/10.3390/cancers11081182

He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD, 2018, 'Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1', Biological Chemistry, 399, pp. 1091 - 1097, http://dx.doi.org/10.1515/hsz-2017-0308

Chen Y; Harrington BS; Lau KCN; Burke LJ; He Y; Iconomou M; Palmer JS; Meade B; Lumley JW; Hooper JD, 2017, 'Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens', Journal of Pharmaceutical and Biomedical Analysis, 139, pp. 65 - 72, http://dx.doi.org/10.1016/j.jpba.2017.02.047

Oancea I; Movva R; Das I; Aguirre De Cárcer D; Schreiber V; Yang Y; Purdon A; Harrington B; Proctor M; Wang R; Sheng Y; Lobb M; Lourie R; Cuív PO; Duley JA; Begun J; Florin THJ, 2017, 'Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism', Gut, 66, pp. 59 - 69, http://dx.doi.org/10.1136/gutjnl-2015-310874

Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR, 2016, 'CD169+ macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer', Journal of Pathology, 239, pp. 218 - 230, http://dx.doi.org/10.1002/path.4718

Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; De Fazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD, 2016, 'Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer', British Journal of Cancer, 114, pp. 417 - 426, http://dx.doi.org/10.1038/bjc.2015.471

He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2016, 'Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance', Oncogene, 35, pp. 468 - 478, http://dx.doi.org/10.1038/onc.2015.101

He Y; Harrington BS; Hooper JD, 2016, 'New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways', Oncoscience, 3, pp. 5 - 8, http://dx.doi.org/10.18632/oncoscience.286

Pinder A; Loo D; Harrington B; Oakes V; Hill MM; Gabrielli B, 2015, 'JIP4 is a PLK1 binding protein that regulates p38MAPK activity in G2 phase', Cellular Signalling, 27, pp. 2296 - 2303, http://dx.doi.org/10.1016/j.cellsig.2015.08.009

Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2015, 'EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface', Oncogene, 34, pp. 1375 - 1383, http://dx.doi.org/10.1038/onc.2014.88

Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B, 2014, 'Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle', Cell Cycle, 13, pp. 3302 - 3311, http://dx.doi.org/10.4161/15384101.2014.949111

Dong Y; Harrington BS; Adams MN; Wortmann A; Stephenson SA; Lisle J; Herington A; Hooper JD; Clements JA, 2014, 'Activation of membrane-bound proteins and receptor systems: A link between tissue kallikrein and the KLK-related peptidases', Biological Chemistry, 395, pp. 977 - 990, http://dx.doi.org/10.1515/hsz-2014-0147

Conference Papers

Harrington BS; Kamdar R; Wong N; House CD; Annunziata CM, 2022, 'Modulating UGDH expression in ovarian cancer tumor-initiating cells alters the tumor microenvironment', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022

Kamdar RD; Harrington BS; Korrapati S; Wong N; House CD; Annunziata CM, 2022, 'NF-κB signaling regulates miRNA expression in ovarian cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022

Kamdar RD; Harrington BS; Korrapati S; Wong N; House CD; Annunziata CM, 2022, 'NF-κB signaling regulates miRNA expression in ovarian cancer.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022

Ning F; Meyer T; Harrington B; Annunziata C, 2022, 'A NON-CANONICAL ROLE FOR CCL2 IN T CELL MIGRATION: IMPROVING DUAL-INTERFERON-TREATED AUTOLOGOUS MONOCYTES AS A THERAPY FOR OVARIAN CANCER', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A427 - A427, http://dx.doi.org/10.1136/jitc-2022-SITC2022.0405

Caminear M; Harrington B; Annunziata C, 2021, 'Disulfiram superior to ALDH1A1 inhibitor analogs in targeting ovarian cancer stem cells.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021

Reynolds B; By S; Witt A; Weinberg Q; Ramkorun B; Harrington B; Ndolo JM; Pastakia D; Esbenshade A; Wellons JC; Smith S; Bhatia A, 2018, 'Oncologic Treatment Effects in the Pediatric Spinal Cord Assessed by Diffusion Tensor Imaging', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S653 - S653

Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD, 2015, 'EGF-induced recycling of the cancer promoting protein CDCP1', in CLINICAL & EXPERIMENTAL METASTASIS, SPRINGER, pp. 210 - 210

Hooper J; He Y; Wu A; Harrington B; Davies C; Wallace S; Gilks B; Perrin L; Armes J, 2014, 'A NEW MARKER OF POOR OUTCOME AND POTENTIAL THERAPEUTIC TARGET IN OVARIAN CLEAR CELL CARCINOMA', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 958 - 959

Purdon A; Ramakrishnan R; Harrington B; Brennan D; Chenevix-Trench G; Munster D; Coward J, 2014, 'STATIN THERAPY INDUCES APOPTOSIS IN PLATINUM RESISTANT OVARIAN CANCER CELLS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 197 - 198

Harrington B; Davies CM; Wallace SJ; He Y; Armes JE; Perrin LC; Hooper JD, 2014, 'TARGETING THE CELL SURFACE PROTEIN CDCP1 IN A MODEL OF ADVANCED OVARIAN CANCER', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 113 - 113

Preprints

Annunziata C; Kudo K; Greer Y; Yoshida T; Harrington B; Korrapati S; Shibuya Y; Henegar L; Kopp J; Fujii T; Lipkowitz S, Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer, http://dx.doi.org/10.21203/rs.3.rs-3399502/v1

Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala J; Dreyer T; Magdolen V; Reuning U; He Y; Tate E; Hooper JD, Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1, http://dx.doi.org/10.21203/rs.3.rs-92391/v1

Lipkowitz S; Kudo K; Crooks D; Greer Y; Yang Y; Brender J; Yoshida T; Harrington B; Kamdar R; Korrapati S; Shibuya Y; Henegar L; Kopp J; Fujii T; Annunziata C, Targeting Metabolic Vulnerability by Combining NAMPT Inhibitors and Disulfiram for Treatment of Recurrent Ovarian Cancer, http://dx.doi.org/10.21203/rs.3.rs-4150814/v1

Harrington BS; Kamdar R; Ning F; Korrapati S; Caminear MW; Hernandez LF; Butcher D; Edmondson E; Traficante N; Group AOCS; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Nag ML; Mazan-Mamczarz K; House CD; Hooper JD; Bowtell DDL; Annunziata CM, UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer, http://dx.doi.org/10.1101/2022.10.07.509566

Back to profile page